Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

101. Dementia Friendly Design Features for Walking Paths: A Focus Practice Question

Dementia Friendly Design Features for Walking Paths: A Focus Practice Question Dementia Friendly Design Features for Walking Paths A Focused Practice Question Kim McAdam, Analyst, Research and Policy Sharon Williams, Supervisor Research, Policy and Planning Team Chronic Disease and Injury Prevention Region of Peel Public Health March 2017 i Table of Contents Key Messages 1 Issue & Context 2 Literature Review Question 4 Literature Search 4 Relevance Assessment 5 Results of the Search 6 Critical (...) Appraisal 6 Description of Included Studies 7 Synthesis of Findings 9 Relevance to Practice 15 References 15 Appendices 15 Appendix A: Search Strategy 16 Appendix B: Literature Search Flowchart 18 Appendix C: Data Extraction Tables 19 1 Key Messages 1. Design features of walking paths that can support older adults with dementia in safe physical activity, recreation and leisure, and social interaction include: continuous circulation loops with destination points and no dead ends, varying route lengths

2018 Peel Health Library

102. Randomised controlled trial: Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations Full Text available with Trip Pro

Randomised controlled trial: Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations Self-management programme for people with dementia and their spouses demonstrates some benefits, but the model has limitations | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Self-management programme for people with dementia and their spouses demonstrates some benefits

2018 Evidence-Based Nursing

103. Management of behavioural and psychological symptoms of dementia by an aroma-massage with acupressure treatment protocol: A randomised clinical trial (Abstract)

Management of behavioural and psychological symptoms of dementia by an aroma-massage with acupressure treatment protocol: A randomised clinical trial This study evaluates the clinical effectiveness of a multicomponent aroma-massage with an acupressure treatment protocol and compared it to cognitive training for the management of behavioural and psychological symptoms of dementia.Pharmacological interventions have been unsatisfactory in managing behavioural and psychological symptoms of dementia (...) ; thus, complementary and alternative medicine has been extensively researched to identify an adjunct safe and cost-effective intervention.This randomised clinical trial utilised a three-arm parallel group design. Cognitive training was used as a conventional intervention to manage behavioural and psychological symptoms of dementia, whereas exercise was considered "treatment as usual" in this study; both were used as comparisons with the experimental protocol. There were three treatment groups: Group

2018 EvidenceUpdates

104. Less dementia with oral anticoagulation in atrial fibrillation Full Text available with Trip Pro

Less dementia with oral anticoagulation in atrial fibrillation The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect.Retrospective registry study of all patients (...) with hospital diagnosis of AF and no previous diagnosis of dementia in Sweden between 2006 and 2014. Propensity score matching, falsification endpoints, and analyses according to intention to treat as well as on-treatment principles were used. The study included 444 106 patients and over 1.5 million years at risk. Patients on anticoagulant treatment at baseline was associated with 29% lower risk of dementia than patients without anticoagulant treatment [hazard ratio (HR) 0.71, 95% confidence intervals (95

2018 EvidenceUpdates

105. Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease

Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease '); } else { document.write(' '); } ACE | Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease Search > > Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease - Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease Published on 5 February 2018 (...) Guidance Recommendation The Ministry of Health's Drug Advisory Committee has recommended: Rivastigmine patch formulation (4.6mg/24h and 9.5mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Parkinson's disease. Rivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Alzheimer's disease. Conditions should be confirmed

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

106. Old age psychiatry: Clinical imaging in dementia with Lewy bodies

Old age psychiatry: Clinical imaging in dementia with Lewy bodies Clinical imaging in dementia with Lewy bodies | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clinical imaging in dementia with Lewy bodies Article Text Clinical review Old age psychiatry Clinical imaging in dementia with Lewy bodies Free Ajenthan Surendranathan , John Tiernan O’Brien Statistics from Altmetric.com Introduction Dementia with Lewy bodies (DLB

2018 Evidence-Based Mental Health

107. Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines

Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness and Guidelines Environmental Restraints for Dementia Patients in Long-Term Care Facilities: Clinical Effectiveness (...) and Guidelines Published on: December 19, 2017 Project Number: RB1177-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of using environmental restraints for geriatric patients with dementia or psychosis in long-term care facilities? What are the evidence-based guidelines regarding the use of environmental restraints for patients with dementia or psychosis in long-term care facilities? Key Message No relevant

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

108. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Full Text available with Trip Pro

18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 18F-florbetaben uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-florbetaben. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-florbetaben

2017 Cochrane

109. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Full Text available with Trip Pro

18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 18F-flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology (...) in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and the confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-flutemetamol. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-flutemetamol

2017 Cochrane

110. Validation of the 6-Item Cognitive Impairment Test and the 4AT test for combined delirium and dementia screening in older Emergency Department attendees Full Text available with Trip Pro

Validation of the 6-Item Cognitive Impairment Test and the 4AT test for combined delirium and dementia screening in older Emergency Department attendees screening for cognitive impairment in Emergency Department (ED) requires short, reliable tools.to validate the 4AT and 6-Item Cognitive Impairment Test (6-CIT) for ED dementia and delirium screening.diagnostic accuracy study.attendees aged ≥70 years in a tertiary care hospital's ED.trained researchers assessed participants using (...) the Standardised Mini Mental State Examination, Delirium Rating Scale-Revised 98 and Informant Questionnaire on Cognitive Decline in the Elderly, informing ultimate expert diagnosis using Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria for dementia and delirium (reference standards). Another researcher blindly screened each participant, within 3 h, using index tests 4AT and 6-CIT.of 419 participants (median age 77 years), 15.2% had delirium and 21.5% had dementia. For delirium detection

2017 EvidenceUpdates

111. Polycystic kidney disease is significantly associated with dementia risk (Abstract)

Polycystic kidney disease is significantly associated with dementia risk Data on the risk of neurodegenerative diseases, including Alzheimer disease (AD) and Parkinson disease (PD), in patients with polycystic kidney disease (PKD) are lacking.A total of 4,229 patients who were aged ≥20 years and had received a diagnosis of PKD were included in the PKD cohort. For each PKD case identified, 1 participant aged ≥20 years without a history of PKD, dementia, or PD was selected from the comparison (...) cohort. For each patient with PKD, the corresponding controls were selected 1:1 on the basis of the nearest propensity score calculated using logistic regression.The incidence density rates of dementia were 4.31 and 2.50 per 1,000 person-years in the PKD and control cohorts, respectively. A 2.04-fold higher risk of dementia was observed in patients with PKD than in controls (adjusted hazard ratio [aHR] 2.04; 95% confidence interval [CI] 1.46-2.85). Regarding the risk of different dementia subtypes

2017 EvidenceUpdates

112. CRACKCast E104 – Delirium and Dementia

CRACKCast E104 – Delirium and Dementia CRACKCast E104 – Delirium and Dementia - CanadiEM CRACKCast E104 – Delirium and Dementia In , by Adam Thomas August 28, 2017 This episode of CRACKCast covers Rosen’s Chapter 94, Delirium and Dementia. These are common presentations in the emergency department, and this episode will focus on screening, diagnosis, and management. Shownotes – Rosens in Perspective: “Delirium is characterized by a fluctuating neurobehavioral disturbance typically progressing (...) over a short period. It is a direct consequence of an acute systemic or central nervous system (CNS) stressor. Dementia, on the other hand, tends to follow a more gradual course, with evolution occurring over months to years. Although patients with dementia exhibit confusion, unlike delirium, manifestations of autonomic nervous system abnormalities are minimal or absent and a disturbance in level of consciousness usually is not a feature.” These big topics fall under the term neurobehavioural

2017 CandiEM

113. Tea, talk and technology: patient and public involvement to improve connected health ‘wearables’ research in dementia Full Text available with Trip Pro

Tea, talk and technology: patient and public involvement to improve connected health ‘wearables’ research in dementia There are a growing number of mobile phones, watches and electronic devices which can be worn on the body to track aspects of health and well-being, such as daily steps, sleep and exercise. Dementia researchers think that these devices could potentially be used as part of future research projects, for example to help spot changes in daily activity that may signal the early (...) symptoms of dementia. We asked a range of older people, including people living with dementia and their carers, to participate in interactive discussions about how future participants might find using these devices as part of research projects. We also invited volunteers to borrow a range of devices to test at home, giving them further insights. Discussions revealed that people were generally supportive of this type of research, provided they gave informed consent and that devices were discreet

2017 Research involvement and engagement

114. Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study Full Text available with Trip Pro

Prevalence of and associations with agitation in residents with dementia living in care homes: MARQUE cross-sectional study Agitation is reportedly the most common neuropsychiatric symptom in care home residents with dementia.To report, in a large care home survey, prevalence and determinants of agitation in residents with dementia.We interviewed staff from 86 care homes between 13 January 2014 and 12 November 2015 about residents with dementia with respect to agitation (Cohen-Mansfield (...) Agitation Inventory (CMAI)), quality of life (DEMQOL-proxy) and dementia severity (Clinical Dementia Rating). We also interviewed residents and their relatives. We used random effects models adjusted for resident age, gender, dementia severity and care home type with CMAI as a continuous score.Out of 3053 (86.2%) residents who had dementia, 1489 (52.7%) eligible residents participated. Fifteen per cent of residents with very mild dementia had clinically significant agitation compared with 33% with mild

2017 BJPsych open

115. Atrophy of the parahippocampal gyrus is prominent in heart failure patients without dementia Full Text available with Trip Pro

Atrophy of the parahippocampal gyrus is prominent in heart failure patients without dementia The exacerbation of heart failure (HF) induces brain damage and cognitive impairment (CI), which frequently attenuates the effects of treatment. However, it is not clear whether HF patients without clinical dementia demonstrate increased risk of CI. We examined whether local atrophy in the parahippocampal gyrus, a potential predictor of CI, is prominent in HF patients without clinical dementia.Twenty (...) stable HF patients with a history of admission due to decompensated HF or presentation of apparent pulmonary congestion following chest X-ray and 17 controls were enrolled in this observational, analytical, cross-sectional, case-control study. Patients with dementia were excluded from this study based on the results of cognitive assessment. Three-dimensional T1 weighted magnetic resonance image analysis was performed to evaluate the severity of local brain atrophy using software based on statistical

2017 ESC heart failure

116. Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia Full Text available with Trip Pro

Selectivity and Kinetic Requirements of HDAC Inhibitors as Progranulin Enhancers for Treating Frontotemporal Dementia Frontotemporal dementia (FTD) arises from neurodegeneration in the frontal, insular, and anterior temporal lobes. Autosomal dominant causes of FTD include heterozygous mutations in the GRN gene causing haploinsufficiency of progranulin (PGRN) protein. Recently, histone deacetylase (HDAC) inhibitors have been identified as enhancers of PGRN expression, although the mechanisms

2017 Cell chemical biology

117. Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. Full Text available with Trip Pro

Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. Objective To forecast dementia prevalence with a dynamic modelling approach that integrates calendar trends in dementia incidence with those for mortality and cardiovascular disease.Design Modelling study.Setting General adult population of England and Wales.Participants The English Longitudinal Study of Ageing (ELSA) is a representative panel study with six waves (...) of data across 2002-13. Men and women aged 50 or more years, selected randomly, and their cohabiting partners were recruited to the first wave of ELSA (2002-03). 11392 adults participated (response rate 67%). To maintain representativeness, refreshment participants were recruited to the study at subsequent waves. The total analytical sample constituted 17 906 people. Constant objective criteria based on cognitive and functional impairment were used to ascertain dementia cases at each wave.Main outcome

2017 BMJ

118. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public (...) , Burke O, Burns A, Clare L, Garrard P, Kehoe P, Passmore P, Holmes C, Maidment I, Murtagh F, Robinson L & Livingston G. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment 2017; 21(26) Authors' objectives To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community

2017 Health Technology Assessment (HTA) Database.

119. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. Full Text available with Trip Pro

Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. Objective To test the hypotheses that physical activity in midlife is not associated with a reduced risk of dementia and that the preclinical phase of dementia is characterised by a decline in physical activity.Design Prospective cohort study with a mean follow-up of 27 years.Setting Civil service departments in London (Whitehall II study).Participants 10 308 participants aged 35-55 years (...) at study inception (1985-88). Exposures included time spent in mild, moderate to vigorous, and total physical activity assessed seven times between 1985 and 2013 and categorised as "recommended" if duration of moderate to vigorous physical activity was 2.5 hours/week or more.Main outcome measures A battery of cognitive tests was administered up to four times from 1997 to 2013, and incident dementia cases (n=329) were identified through linkage to hospital, mental health services, and mortality

2017 BMJ

120. Assistive technology for memory support in dementia. Full Text available with Trip Pro

Assistive technology for memory support in dementia. The sustained interest in electronic assistive technology in dementia care has been fuelled by the urgent need to develop useful approaches to help support people with dementia at home. Also the low costs and wide availability of electronic devices make it more feasible to use electronic devices for the benefit of disabled persons. Information Communication Technology (ICT) devices designed to support people with dementia are usually referred (...) to as Assistive Technology (AT) or Electronic Assistive Technology (EAT). By using AT in this review we refer to electronic assistive devices. A range of AT devices has been developed to support people with dementia and their carers to manage their daily activities and to enhance safety, for example electronic pill boxes, picture phones, or mobile tracking devices. Many are commercially available. However, the usefulness and user-friendliness of these devices are often poorly evaluated. Although reviews

2017 Cochrane